Published in Acta Diabetol Lat on April 15, 1977
Serum potassium responses to nebulized salbutamol administered during an acute asthmatic attack. Arch Emerg Med (1989) 0.75
Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest (2002) 1.65
Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest (2000) 1.44
Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex. J Cereb Blood Flow Metab (1997) 1.44
Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease. J Endocrinol Invest (2003) 1.43
Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002-2004: Data from the GH Registry. J Endocrinol Invest (2006) 1.39
Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine. J Clin Endocrinol Metab (1975) 1.37
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab (2001) 1.32
Propranolol block of epinephrine-induced hypokaliaemia in man. Eur J Pharmacol (1970) 1.29
Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. Neuroendocrinology (1980) 1.19
Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int J Obes Relat Metab Disord (1999) 1.11
Bone metabolism in type 2 diabetes mellitus. Acta Diabetol (1999) 1.08
Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J Clin Endocrinol Metab (1996) 1.03
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab (2000) 0.98
Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy. Clin Endocrinol (Oxf) (1990) 0.97
Radioimmunoassay of human growth hormone. J Nucl Biol Med (1970) 0.97
Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. J Clin Endocrinol Metab (2000) 0.97
Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test. J Clin Endocrinol Metab (2000) 0.96
Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab (1998) 0.95
New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol (1996) 0.94
Arginine-induced hypophosphatemia and hyperkaliemia in man. Diabete Metab (1979) 0.94
The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. J Clin Endocrinol Metab (1999) 0.94
Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. Metabolism (1992) 0.91
The role of insulin in beta 2-receptor mediated hypokalemia. Clin Endocrinol (Oxf) (1985) 0.91
Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults. Neuroendocrinology (1991) 0.90
Depressed tolbutamide-induced insulin response in subjects treated with propranolol. Diabetologia (1971) 0.90
Reciprocal pattern of the TSH and PRL responses to dopamine receptor blockade in women with physiological or pathological hyperprolactinaemia. Clin Endocrinol (Oxf) (1983) 0.89
Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine (2001) 0.89
Biologic activities of growth hormone secretagogues in humans. Endocrine (2001) 0.88
True hermaphroditism with XX/XY sex chromosome mosaicism: report of a case. Clin Genet (1976) 0.88
Approach to the diagnosis of hyperprolactinemic states: the nomifensine and domperidone tests. Panminerva Med (1981) 0.87
Defective regulation of prolactin secretion after successful removal of prolactinomas. J Clin Endocrinol Metab (1983) 0.84
Neuroactive drugs in growth disorders. Acta Paediatr Scand Suppl (1990) 0.83
Increased renal phosphate excretion in Cushing's syndrome. Acta Endocrinol (Copenh) (1967) 0.83
N-acetylcysteine is able to reduce the oxidation status and the endothelial activation after a high-glucose content meal in patients with Type 2 diabetes mellitus. J Endocrinol Invest (2009) 0.83
Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. J Clin Endocrinol Metab (2001) 0.82
Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans. Eur J Endocrinol (2000) 0.82
Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly. Acta Endocrinol (Copenh) (1977) 0.82
Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. Eur J Endocrinol (1996) 0.82
Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women. Eur J Endocrinol (1997) 0.82
Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. Am J Physiol (1999) 0.82
Comparisons among old and new provocative tests of GH secretion in 178 normal adults. Eur J Endocrinol (2000) 0.81
Initial treatment of thyrotoxic Graves' disease with methimazole: a randomized trial comparing different dosages. J Endocrinol Invest (1987) 0.81
Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. Eur J Endocrinol (1996) 0.81
Diagnosis and drug therapy of prolactinoma. Drugs (1996) 0.81
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab (1994) 0.81
Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of adrenocortical tumour. Clin Endocrinol (Oxf) (1995) 0.80
Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. J Clin Endocrinol Metab (1990) 0.80
Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest (1997) 0.80
Classification of red wines by chemometric analysis of voltammetric signals from PEDOT-modified electrodes. Anal Chim Acta (2009) 0.80
Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications. Drugs (1991) 0.80
Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Baillieres Clin Endocrinol Metab (1998) 0.79
A new pharmacological approach to the diagnosis of hyperprolactinaemic states: the nomifensine test. Acta Endocrinol (Copenh) (1980) 0.79
Natural killer activity in hyperprolactinemic patients. Immunopharmacology (1989) 0.79
Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension. J Endocrinol Invest (1998) 0.79
Increase in plasma growth hormone concentration in man after infusion of adrenaline-propranolol. J Endocrinol (1970) 0.79
Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects. J Clin Endocrinol Metab (1977) 0.79
Hyperprolactinaemia and prolactin binding in benign intracranial tumours. J Neurosurg Sci (2001) 0.79
Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans. Eur J Endocrinol (2000) 0.79
Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab (1997) 0.79
Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine. Clin Endocrinol (Oxf) (1990) 0.79
Effect of galanin on basal and stimulated secretion of prolactin, gonadotropins, thyrotropin, adrenocorticotropin and cortisol in humans. Eur J Endocrinol (1995) 0.79
Glucagon is an ACTH secretagogue as effective as hCRH after intramuscolar administration while it is ineffective when given intravenously in normal subjects. Pituitary (2000) 0.79
Effect of various adrenergic receptor stimulating and blocking agents on human growth hormone secretion. J Endocrinol (1972) 0.79
In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose. J Clin Endocrinol Metab (1995) 0.79
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. J Clin Endocrinol Metab (1995) 0.78
Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab (2001) 0.78
Hypothalamic growth hormone-insulin-like growth factor-I axis across the human life span. J Pediatr Endocrinol Metab (2000) 0.78
Human aging and the GH-IGF-I axis. J Pediatr Endocrinol Metab (1996) 0.78
The risk of pronounced hyperkalaemia after arginine infusion in the diabetic subject. Diabete Metab (1981) 0.78
Interaction of free fatty acids and arginine on growth hormone secretion in man. Metabolism (1994) 0.78
IGF-1 levels in different conditions of low somatotrope secretion in adulthood: obesity in comparison with GH deficiency. Minerva Endocrinol (1999) 0.78
Short procedure of GHRH plus arginine test in clinical practice. Pituitary (2001) 0.78
Galanin positively modulates prolactin secretion in normal women. J Endocrinol Invest (1996) 0.78
Increased renal tubular reabsorption of phosphorus in acromegaly. J Clin Endocrinol Metab (1968) 0.78
Implantation of the sella turcica with 90-yttrium in the treatment of Cushing's syndrome of pituitary origin. J Clin Endocrinol Metab (1967) 0.78
Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. J Clin Endocrinol Metab (1996) 0.78
Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man. Acta Endocrinol (Copenh) (1986) 0.78
Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. J Endocrinol Invest (2002) 0.78
Increased thyrotrophin and prolactin secretion induced by domperidone in hypothyroid subjects. Acta Endocrinol (Copenh) (1981) 0.78
The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome. Dementia (1997) 0.77
Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity. Metabolism (1996) 0.77